Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)

INTRODUCTION: In LUX-Lung 3 and LUX-Lung 6, afatinib significantly improved progression-free survival (PFS) versus chemotherapy in patients with tumors harboring common epidermal growth factor receptor (EGFR) mutations (Del19/L858R) and significantly improved overall survival (OS) in patients with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yi-Long, Hirsh, Vera, Sequist, Lecia V., Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, Huang, Yunchao, Schuler, Martin, Mok, Tony, Yamamoto, Nobuyuki, O’Byrne, Kenneth, Geater, Sarayut L., Zhou, Caicun, Massey, Dan, Märten, Angela, Lungershausen, Juliane, Yang, James Chih-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766712/
https://www.ncbi.nlm.nih.gov/pubmed/29178024
http://dx.doi.org/10.1007/s40271-017-0287-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766712/
https://www.ncbi.nlm.nih.gov/pubmed/29178024
http://dx.doi.org/10.1007/s40271-017-0287-z

Ejemplares similares